Abstract | BACKGROUND: CASE PRESENTATION: We report the first case of recurrent pseudogout, an inflammatory crystal arthritis, in a patient treated with nivolumab, a PD-1 inhibitor, for renal cell carcinoma. The patient had recurrent pseudogout flares about week to 10 days after each nivolumab infusion. After treatment with prophylactic colchicine, the patient well tolerated additional nivolumab infusions without adverse events. In parallel, we characterized immune cells of synovial fluid at each flare. Immunoprofiling of synovial fluid showed that the proportion of inflammatory IL-17-producing CD4+ T cells and amount of IL-17 were notably increased in synovial fluid with every recurrent flair, and correlated with the increase in number of synovial neutrophils, suggesting a potential role of T helper 17 (Th17) cells in neutrophil-driven inflammation during pseudogout arthritis. CONCLUSIONS:
|
Authors | Sang T Kim, Mohamad Bittar, Hyun J Kim, Sattva S Neelapu, Amado J Zurita, Roza Nurieva, Maria E Suarez-Almazor |
Journal | Journal for immunotherapy of cancer
(J Immunother Cancer)
Vol. 7
Issue 1
Pg. 126
(05 14 2019)
ISSN: 2051-1426 [Electronic] England |
PMID | 31088575
(Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Immunological
- Biomarkers
- Cytokines
- PDCD1 protein, human
- Programmed Cell Death 1 Receptor
- Nivolumab
|
Topics |
- Antineoplastic Agents, Immunological
(adverse effects, therapeutic use)
- B-Lymphocytes
(immunology, metabolism)
- Biomarkers
- Carcinoma, Renal Cell
(complications, diagnosis, drug therapy)
- Chondrocalcinosis
(diagnosis, etiology, metabolism)
- Cytokines
(metabolism)
- Disease Progression
- Humans
- Male
- Middle Aged
- Nivolumab
(adverse effects, therapeutic use)
- Programmed Cell Death 1 Receptor
(antagonists & inhibitors)
- Recurrence
- Synovial Fluid
(metabolism)
- T-Lymphocytes
(immunology, metabolism)
|